Key facts
- Biomason’s last known valuation is $186.7M (Dec 2024).
- It has raised $132.9M across 6 recorded rounds; the latest was Early Stage VC ($36.7M) in Dec 2024.
- Notable investors include US National Science Foundation, United States Department of War, Novo Holdings, Celesta Capital, 2150 — 12 tracked in total.
- Biomason has filed 7 Form Ds with the SEC since 2013, most recently Jan 2025 ($36.7M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Biomason
Funding rounds
6 roundsAbout Biomason
Developer of a building materials technology designed to harness biology to produce high-quality concrete, replace Portland cement, and cut carbon emissions. The company's technology combines natural microorganisms and chemical processes to develop masonry materials at room temperature, which helps replace traditional clay and concrete and the energy consumption associated with standard manufacturing them, enabling builders to acquire alternative building materials that are produced carbon-free.
- Sector
- Materials and Resources
- HQ
- Durham, NC, United States
- Founded
- 2012
- Employees
- 59
- Website
- biomason.com/
- Ownership
- Privately Held (backing)
Biomason doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biomason shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biomason in its N-PORT filings yet. We sweep new filings monthly.